Patents by Inventor Douglas Clary

Douglas Clary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating osteoporosis
    Patent number: 10166225
    Abstract: This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: January 1, 2019
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Douglas Clary
  • Method for Treating Osteoporosis
    Publication number: 20140228401
    Abstract: This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Application
    Filed: September 20, 2012
    Publication date: August 14, 2014
    Applicant: Exelixis, Inc.
    Inventors: Dana T. Aftab, Douglas Clary
  • Novel human protein kinases and protein kinase-like enzymes
    Publication number: 20060216730
    Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified and their protein structure predicted.
    Type: Application
    Filed: December 29, 2005
    Publication date: September 28, 2006
    Inventors: Gregory Plowman, David Whyte, Gerard Manning, Sucha Sudarsanam, Ricardo Martinez, Peter Flanagan, Douglas Clary
  • Diagnosis and treatment of alk-7 related disorders
    Publication number: 20050026184
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Application
    Filed: May 20, 2004
    Publication date: February 3, 2005
    Inventors: Gregory Plowman, Douglas Clary
  • Diagnosis and treatment of ALK-7 related disorders
    Publication number: 20040234540
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Application
    Filed: May 20, 2004
    Publication date: November 25, 2004
    Applicant: SUGEN, INC.
    Inventors: Gregory D. Plowman, Douglas Clary
  • Diagnosis and treatment of alk-7 related disorders
    Patent number: 6818440
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: November 16, 2004
    Assignee: Sugen, Inc.
    Inventors: Gregory D. Plowman, Douglas Clary
  • Diagnosis and treatment of ALK-7 related disorders
    Publication number: 20040219139
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Application
    Filed: May 20, 2004
    Publication date: November 4, 2004
    Applicant: SUGEN, INC.
    Inventors: Gregory D. Plowman, Douglas Clary
  • DIAGNOSIS AND TREATMENT OF ALK-7 RELATED DISORDERS
    Publication number: 20030073143
    Abstract: The present invention relates to ALK-7 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for ALK-7 related diseases or conditions characterized by an abnormal interaction between an ALK-7 polypeptide and an ALK-7 binding partner.
    Type: Application
    Filed: April 27, 1998
    Publication date: April 17, 2003
    Inventors: GREGORY D. PLOWMAN, DOUGLAS CLARY
  • METHODS OF EVALUATING SPECIFIC CELLULAR FUNCTIONS OF RECEPTOR PROTEIN TYROSINE KINASES IN A LIGAND INDEPENDENT MANNER
    Publication number: 20020068361
    Abstract: The invention relates to methods of evaluating the specific function of a receptor protein tyrosine kinase in cells. The methods activate the receptor in a ligand independent fashion. In addition, the invention includes methods of identifying compounds that modulate receptor protein tyrosine kinase function.
    Type: Application
    Filed: April 7, 1998
    Publication date: June 6, 2002
    Inventor: DOUGLAS CLARY
  • Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
    Patent number: 6235769
    Abstract: The invention relates in part to a method of preventing or treating an abnormal condition caused by an aberration in the function of the C-RET receptor, and specifically to the treatment and prevention of neurodegenerative disorders by administering a pharmaceutical composition that modulates the function of the C-RET receptor.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: May 22, 2001
    Assignee: Sugen, Inc.
    Inventor: Douglas Clary